



## Any berry good solutions to preventing UTIs: Cranberries?

### CLINICAL QUESTION

Do cranberry products prevent recurrent urinary tract infections (UTIs)?

### BOTTOM LINE

Potential benefits of cranberry products for UTI prevention are at high risk-of-bias from potential publication bias, small studies, and unblinding. If biases disregarded, cranberry products might reduce the proportion of women with recurrent UTIs from 24% to 18% over  $\leq 1$  year. Results are inconsistent between patient populations; example children with recurrent UTIs may benefit but not institutionalized elderly or pregnant woman.

### EVIDENCE

- 5 systematic reviews [7-50 randomized control trials (RCTs), 1498-8857 patients].<sup>1-5</sup> UTI definition varied: Symptoms, bacteriuria, or both. Results statistically different unless stated.
- Most recent/largest systematic review (50 RCTs, 8857 patients).<sup>1</sup> "People-at-risk" subgroups included women (generally  $\geq 2$  UTIs/year) or children (1-18 years with  $\geq 1$  past UTI), adults with pelvic radiation/surgery/transplant or neuromuscular dysfunction, institutionalized elderly, and pregnant women. Any cranberry product versus placebo or no-treatment.  $\geq 1$  UTI at 1-12 months (reporting subgroups, due to inconsistent results):

- Women (8 RCTs, 1555 patients): 18% versus 24% placebo, Number Needed to Treat (NNT)=17.
- Children (5 RCTs, 504 patients): 16% versus 34% placebo, NNT=6.
- Adults following pelvic radiation/surgery/transplant (6 RCTs, 1434 patients): 11% versus 23% placebo, NNT=9.
- Institutionalized adults, pregnant women, or neuromuscular dysfunction: No statistical difference.
- Other systematic reviews: Women with recurrent UTIs<sup>2,3</sup> and any “people-at-risk”<sup>4,5</sup> report benefits.
- Adverse events: No difference.<sup>1</sup>
- Limitations:
  - Publication bias:<sup>5</sup> UTI prevention Risk Ratio (RR)=0.68 [Confidence Interval (CI):0.57-0.80] worsens when adjusted for missing studies [RR=0.83 (CI:0.70-1.00)].
  - Systematic reviews<sup>1-5</sup> did no analysis by quality. PEER performed quality analysis for study size and placebo-controlled (in women with recurrent UTI).<sup>1</sup>
    - Smaller RCTs RR=0.47 (CI:0.33-0.68) versus large RCTs RR=0.97 (CI:0.77-1.22), statistically different.
    - No-placebo (unblinded) RCTs RR=0.39 (CI:0.21-0.74) versus placebo RR=0.83 (CI:0.62-1.10), statistically different.

## CONTEXT

- Proanthocyanidin (proposed active ingredient) studied dose varied 2.8-118 mg.
- For women, typical cranberry intervention was juice (1/2-3 cups/day) or capsule (500mg/day).<sup>1</sup>
- Cranberry juice versus capsules (1 RCT, 100 patients):<sup>6</sup> No statistical difference.
- Daily antibiotics reduce recurrence to 12% over 6-12 months versus 66% with placebo.<sup>7</sup>
- Guidelines support antibiotic prophylaxis with conditional recommendation for cranberry.<sup>8</sup>
- Costs:<sup>9</sup> Juice/cup: ~\$0.60; 110 calories (low-calorie: 10 calories).
- Capsules: ~\$0.15-0.63/capsule (doses vary).

## REFERENCES

1. Williams G, Hahn D, Stephens JH, *et al.* Cochrane Database Syst Rev. 2023; 4(4):CD001321.
2. Valente J, Pendry BA, Galante E. J Herbal Med. 2022;36; 100602.
3. Fu Z, Liska D, Talan D, *et al.* J Nutr. 2017; 147(12):2282-2288.
4. Xia JY, Yang C, Xu DF, *et al.* PLoS One. 2021; 16(9):e0256992.
5. Luís Â, Domingues F, Pereira L. J Urol. 2017; 198(3):614-621.
6. Stothers L. Can. J Urol. 2002; 9(3):1558-62.
7. Finley C, Falk J, Korownyk T. Tools for Practice #322 (online publication), College of Family Physicians of Canada, 2022; Sept. 6. Available at: <https://cfpclearn.ca/tfp322/> Accessed on: November 23, 2023.
8. Anger J, Lee U, Ackerman AL, *et al.* J Urol. 2019; 202(2):282-289.

## AUTHORS

**Jennifer Young**, MD CCFP  
**Michael Allan**, MD CCFP  
**Betsy Thomas**, BSc Pharm

*Authors do not have any conflicts of interest to declare.*

9. Real Canadian Superstore website. Available at: <https://www.realcanadiansuperstore.ca>. Accessed on October 25, 2023.

---

**TOOLS FOR PRACTICE  
PROVIDED BY**



---

**IN PARTNERSHIP WITH**



**Tools for Practice** are peer reviewed and summarize practice-changing medical evidence for primary care. Coordinated by **Dr. G. Michael Allan** and **Dr. Adrienne Lindblad**, they are developed by the Patients, Experience, Evidence, Research (PEER) team, and supported by the College of Family Physicians of Canada, and the Alberta, Ontario, and Saskatchewan Colleges of Family Physicians. Feedback is welcome and can be sent to [toolsforpractice@cfpc.ca](mailto:toolsforpractice@cfpc.ca). Archived articles can be found at [www.toolsforpractice.ca](http://www.toolsforpractice.ca)

*This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the College of Family Physicians of Canada.*